Selpercatinib Monotherapy

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

Trial Timeline

Jul 29, 2024 → Nov 1, 2031

NCT ID

NCT06458036

About Selpercatinib Monotherapy

Selpercatinib Monotherapy is a phase 2 stage product being developed by Eli Lilly for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06458036. Target conditions include Differentiated Thyroid Cancer, Pediatric Cancer, Cancer.

What happened to similar drugs?

1 of 8 similar drugs in Differentiated Thyroid Cancer were approved

Approved (1) Terminated (1) Active (6)

✅sunitinibPfizerApproved

🔄Abemaciclib + PlaceboEli LillyPhase 3

🔄Lenvatinib + PlaceboEisaiPhase 3

❌Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3

🔄Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placeboNovartisPhase 3

🔄Vandetanib (SAR390530) + PlaceboSanofiPhase 3

🔄Thyrogen (thyrotropin alfa for injection)SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06458036	Phase 2	Recruiting	Jul 29, 2024	Nov 1, 2031	Differentiated Thyroid Cancer

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	22
Abemaciclib + Placebo	Eli Lilly	Phase 3	44
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
Selumetinib + Placebo + Radioactive Iodine Therapy	AstraZeneca	Phase 3	32
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	42
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Everolimus + Sorafenib	Novartis	Phase 2	31
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo	Novartis	Phase 3	44
PDR001	Novartis	Phase 2	35
Everolimus (Afinitor®)	Novartis	Phase 2	35
Sacituzumab govitecan	Gilead Sciences	Phase 2	42
sunitinib	Pfizer	Approved	43
Vandetanib (SAR390530) + Placebo	Sanofi	Phase 3	40
Thyrogen (thyrotropin alfa for injection)	Sanofi	Phase 3	40
Cabazitaxel	Sanofi	Phase 2	35
Larotrectinib monotherapy	Bayer	Phase 2	39